Team

Youdim_image_01Prof Moussa Youdim – President, CSO

A world-renowned expert in pharmacology, Prof. Youdim is the inventor and developer of the innovative Parkinson’s disease drug “Azilect”, Teva’s second largest innovative blockbuster, with annual revenues on $700M, and Selegiline, an MAO-B inhibitor for Parkinson’s disease treatment. Prof. Youdim has extensive experience in the pharmaceutical industry, professor emeritus at the Technion, where he was the head of the Department of Pharmacology at the Faculty of Medicine for over 30 years.

AAEAAQAAAAAAAAMfAAAAJGRhMDc0YzFhLTU5ODYtNGViNi05NzNjLTI4MGVmMDliZmFmNQTal Youdim – CEO

As an expert in the area of medical devices with vast experience in engineering and 3D modeling, Tal Youdim joined Youdim to support the technical aspect of the incubator’s work. In the past he has worked on development of mitral valve replacement & repair technology, Central venous catheter technology and drug device combinations. Today, he is responsible for all developments related to medical devices, drug administration devices and operations.

heldmanProf. Eliyahu Heldman – BOD Member

A professor emeritus at Ben-Gurion University, with over 40 years’ experience in neuroscience research, Prof. Heldman’s experience includes work at NIH and evaluation of CNS-active drugs at the Israel Institute for Biological Research. In 2003, he co-founded NeuroDerm Ltd., Israel (NASDAQ: NDRM). Prof. Heldman was also a co-inventor of Cevimeline (EvoxacTM), an FDA-approved muscarinic agonist, for the treatment of Sjögren’s syndrome. He has published over 130 scientific articles, is co-inventor of more than 10 patents and has edited two books on the subject of neuroactive drugs.

oded meiriOded Meiri – BOD Member

Proven track record in leading projects from idea into products in the Industry. Oded served as CEO of MitralHeal and in variety of senior R&D positions in the medical device filed (Pi-Cardia, Enopace Biomedical, Edwards LifeSciences). Experience in establishments of new technologies/IP’s and multi-International companies projects bring-up and management. Over 35 patents in the biomedical and industrial fields. Oded holds B.Sc, in Mechanical engineering and ME, in system engineering, both are from the Technion Israel institute of technology.

efrat-1Efrat Herscovitch – CFO

With extensive experience in the area of Technological incubators, Efrat has over 20-years experience with start-up companies, having served in various financial positions at incubators. Prior joining TerraLab, she served in various finance positions as CFO and Finance controller in Israeli companies such as Eltam Technological Incubator, Naiot Technological Center, L.N. innovative Technology Ltd and has rendered financial services to the project companies during and post the incubation period.

Scientific Advisory Board

Prof. Moussa Youdim, a world-renowned expert in pharmacology, is Youdim’s Chairman. Prof. Youdim is the inventor and developer of the innovative Parkinson’s disease drug “Azilect”, Teva’s second largest innovative blockbuster, with annual revenues on $700M, and Selegiline, an MAO-B inhibitor for Parkinson’s disease treatment. Prof. Youdim has extensive experience in the pharmaceutical industry, professor emeritus at the Technion, where he was the head of the Department of Pharmacology at the Faculty of Medicine for over 30 years.

Prof. Eliyahu Heldman, A professor emeritus at Ben-Gurion University, with over 40 years’ experience in neuroscience research, Prof. Heldman’s experience includes work at NIH and evaluation of CNS-active drugs at the Israel Institute for Biological Research. In 2003, he co-founded NeuroDerm Ltd., Israel (NASDAQ: NDRM). Prof. Heldman was also a co-inventor of Cevimeline (EvoxacTM), an FDA-approved muscarinic agonist, for the treatment of Sjögren’s syndrome. He has published over 130 scientific articles, is co-inventor of more than 10 patents and has edited two books on the subject of neuroactive drugs.

Prof. Martin Rabey, Prof. Rabey is board certified in general neurology, with a sub-specialty in Parkinson’s disease and Alzheimer’s disease. He is the former chair of the Department of Neurology at Assaf HaRofe Medical Center.

Prof. Peter Riederer, is a German neuroscientist with several thousands of citations and around 950 scientific writings. He has published more than 620 scientific papers in peer-reviewed scientific journals that are indexed in MEDLINE, the most referent biomedical scientific database. He has also been author and co-author of more than 20 books relevant to the fields of neuroscience, psychiatry and neurology.

Prof. Shimon Amsalem, Engaged in drug discovery and development of innovative new chemical entities with over 20 years of experience in the pharmaceutical industry. Worked in a multidisciplinary environment in technical and R&D areas from preclinical to GMP production of injectable, ocular, oral, and topical drug products. Involved in the pharmaceutical development of 30 new products, 6 of them marketed in the US and Europe. Made significant contributions to five NDA (New Drug Application) approvals by the FDA and four IND (Investigational New drugs), in Phase II/III clinical trials.

Dr. Natalie Dror, A Biotech PhD engineer with over ten years’ experience in conducting and leading academic & industrial research. Certified CRA, Experienced in the analyses and evaluations of clinical data, investigator and site compliance assurance, protocol writing, FDA regulations, ICH Guidelines, and GCP. Experienced in the fields of clinical trials, biomarker discovery, personalized medicine, and medical device development.